Senhwa Biosciences

Senhwa Biosciences, Inc.Founded in 2012 and headquartered in San Diego, US, Senhwa Biosciences specializes in cancer therapeutics.Senhwa Biosciences, Inc. focuses on developing next-generation DNA Damage Response (DDR) therapeutics specifically designed for cancer treatment. The company's lead products, CX-5461 and CX-4945, are first-in-class small molecule drugs currently undergoing Phase I/II clinical trials in multiple countries, including Australia, Canada, the United States, Korea, and Taiwan. These compounds aim to address critical needs in oncology by targeting specific pathways in cancer cell survival and proliferation, ultimately enhancing patient outcomes. The primary users of these therapeutics include oncologists and healthcare institutions that treat cancer patients, providing them with innovative options to combat various forms of the disease.Senhwa Biosciences, Inc. generates revenue primarily through partnerships and collaborations within the pharmaceutical and biotechnology sectors. The company engages in transactions that facilitate the development and commercialization of its DDR therapeutics, which may include licensing agreements with larger pharmaceutical companies or joint ventures aimed at advancing clinical trials. Revenue generation is bolstered by successful clinical milestones and potential licensing fees accrued from future product commercialization. While specific pricing plans for its products are not publicly disclosed, the revenue model typically involves structured partnerships that could lead to milestone payments tied to the progress of clinical trials and subsequent product launches.Senhwa Biosciences is focused on advancing its lead products, CX-5461 and CX-4945, through clinical trials and preparing for future launches.

1. Series B

   Dec 12, 2013

   Amount

   $17M

   Investors

   Locked